公开(公告)号：US20220265823A1

公开(公告)日：2022-08-25

申请号：US17738846

申请日：2022-05-06

Applicant: Novartis AG

Inventor： Shinji HATAKEYAMA ,  Ronenn ROUBENOFF ,  Estelle TRIFILIEFF ,  Jerome FEIGE ,  Lloyd B. KLICKSTEIN

IPC: A61K39/395 ,  A61P21/00 ,  A61P35/00 ,  A61K33/243 ,  A61K31/436

Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：US20200181271A1

公开(公告)日：2020-06-11

申请号：US16626170

申请日：2018-06-26

Applicant: NOVARTIS AG

Inventor： Shinji HATAKEYAMA ,  Michaela KNEISSEL ,  Estelle TRIFILIEFF

IPC: C07K16/28 ,  A61P13/00

Abstract: The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.

公开(公告)号：US20240425602A1

公开(公告)日：2024-12-26

申请号：US18424004

申请日：2024-01-26

Applicant: Novartis AG

Inventor： Catrin BERGER ,  Tanja HERRMANN ,  Chris LU ,  Kelly-Ann SHEPPARD ,  Estelle TRIFILIEFF ,  Stefanie URLINGER

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07H21/04

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

公开(公告)号：US20220340668A1

公开(公告)日：2022-10-27

申请号：US17639862

申请日：2020-09-01

Applicant: Novartis AG

Inventor： Laura COLEMAN ,  C. Daniel MEYERS ,  Ronenn ROUBENOFF ,  Estelle TRIFILIEFF

IPC: C07K16/28 ,  A61P1/16 ,  A61P3/10

Abstract: The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof. The present disclosure also relates to pharmaceutical combinations comprising such ActRII antagonists and at least one further therapeutic agent in the treatment or prevention of liver disease or disorder.

公开(公告)号：US20170260275A1

公开(公告)日：2017-09-14

申请号：US15529594

申请日：2015-12-04

Applicant: Novartis AG

Inventor： Patrick KORTEBEIN ,  Daniel ROOKS ,  Lloyd B. KLICKSTEIN ,  Ronenn ROUBENOFF ,  David GLASS ,  Estelle TRIFILIEFF ,  Dimitris PAPANICOLAOU

IPC: C07K16/28

Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.